<DOC>
	<DOC>NCT00191022</DOC>
	<brief_summary>This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.</brief_summary>
	<brief_title>Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Male or female outpatients at least 18 years of age and not more than 65 years of age. Must sign the informed consent document. Present at Visit 1 with social anxiety disorder based on a Clinical Global ImpressionSeverity score of greater than or equal to 4. Females of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use both a reliable primary method of birth control. Judged to be reliable and willing to keep all appointments for clinic visits, tests, and procedures required by the protocol. Have any comorbid Axis I disorders (such as major depression, obsessive compulsive disorder, posttraumatic stress disorder, or panic disorder), in the opinion of the investigator, if the disorder occurred within the last 6 months. Have had any previous or current diagnoses of bipolar disorders, schizophrenia, or other psychotic disorders. Have the presence of an Axis II disorder, except avoidant personality disorder. Have a serious medical illness. Have abnormal thyroidstimulating hormone (TSH) concentrations or are taking thyroid supplements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>